|
|||||
|
|
| 冠心病介入治疗术后造影剂肾病的药物防治进展 | |
| 引用本文： | 吴玉付. 冠心病介入治疗术后造影剂肾病的药物防治进展[J]. 影像研究与医学应用, 2020, 0(10): 3-7 |
| 作者姓名： | 吴玉付 |
| 作者单位： | 柳州市中医医院心病科 |
| 摘 要： | 造影剂肾病(CIN)是院内获得性急性肾功能衰竭的主要原因之一,随着经皮冠状动脉介入术(PCI)广泛深入开展,CIN已成为PCI术后严重并发症,严重影响冠心病患者介入术后预后。如何药物防治冠心病介入术后CIN是目前临床关注的重点。本文对心血管内科具有预防CIN作用的药物进行综述,为临床防治CIN提供一定的指导。 |
| 关 键 词： | 冠心病 介入治疗 造影剂肾病 药物 |
Progress in drugs on the prevention and treatment of contrast-induce nephropathy in patients with coronary heart disease after percutaneous coronary intervention |
|
| Wu Yufu. Progress in drugs on the prevention and treatment of contrast-induce nephropathy in patients with coronary heart disease after percutaneous coronary intervention[J]. Journal of Imaging Research and Medical Applications, 2020, 0(10): 3-7 | |
| Authors: | Wu Yufu |
| Affiliation: | (Department of Cardiology,Liuzhou Traditional Chinese Medical Hospital,Liuzhou,Guangxi 545001 China) |
| Abstract: | Contrast-induce nephropathy(CIN)is one of the main causes of hospital-acquired acute renal failure.With the widespread and in-depth development of percutaneous coronary intervention(PCI),CIN has become a serious complication after PCI,which seriously affects the prognosis of patients with coronary heart disease after PCI.How to prevent and treat CIN in patients with coronary heart disease after PCI is the focus of clinical attention.This article reviews the drugs used in the field of cardiovascular medicine and has the role of preventing CIN,and provides some guidance for the clinical prevention and treatment of CIN. |
| Keywords: | Coronary heart disease Percutaneous coronary intervention(PCI) Contrast-induce nephropathy Drugs |
| 本文献已被 维普 等数据库收录！ | |